Receptor 5-HT2B (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Receptor 5-HT2B" in Spanish language version.

refsWebsite

Global rank Spanish rank

35nih.gov

4^th place

33doi.org

2^nd place

11archive.org

6^th place

5^th place

2archives-ouvertes.fr

1,031^st place

2,356^th place

2issn.org

57^th place

3^rd place

2harvard.edu

18^th place

34^th place

2web.archive.org

1^st place

1worldcat.org

5^th place

10^th place

1eurekaselect.com

low place

5,319^th place

1inserm.fr

9,568^th place

low place

1nytimes.com

7^th place

15^th place

1sciencedirect.com

149^th place

128^th place

1rcsb.org

8,838^th place

low place

1opus-bayern.de

low place

1researchgate.net

120^th place

124^th place

1unc.edu

1,538^th place

1,360^th place

1alcobra-pharma.com

low place

1guidetopharmacology.org

low place

alcobra-pharma.com

«Metadoxine extended release (MDX) for adult ADHD». Alcobra Ltd. 2014. Archivado desde el original el 13 de febrero de 2019. Consultado el 7 de mayo de 2014.

archive.org

Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM (June 1995). «The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors». British Journal of Pharmacology 115 (4): 622-8. PMC 1908489. PMID 7582481. doi:10.1111/j.1476-5381.1995.tb14977.x.
Monassier L, Laplante MA, Jaffré F, Bousquet P, Maroteaux L, de Champlain J (Aug 2008). «Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice». Hypertension 52 (2): 301-7. PMID 18591460. doi:10.1161/HYPERTENSIONAHA.107.105551.
Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ (Sep 1999). «Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells». British Journal of Pharmacology 128 (1): 13-20. PMC 1571597. PMID 10498829. doi:10.1038/sj.bjp.0702751.
Kennett GA, Trail B, Bright F (Dec 1998). «Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated». Neuropharmacology 37 (12): 1603-10. PMID 9886683. doi:10.1016/S0028-3908(98)00115-4.
Görnemann T, Hübner H, Gmeiner P, Horowski R, Latté KP, Flieger M, Pertz HH (Mar 2008). «Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors». The Journal of Pharmacology and Experimental Therapeutics 324 (3): 1136-45. PMID 18096760. doi:10.1124/jpet.107.133165.
Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D (Sep 2003). «The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways». The Journal of Pharmacology and Experimental Therapeutics 306 (3): 954-64. PMID 12750432. doi:10.1124/jpet.103.051797.
Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (Apr 1998). «Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors». Psychopharmacology 136 (4): 409-14. PMID 9600588. doi:10.1007/s002130050585.
Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP (Nov 2004). «The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo». British Journal of Pharmacology 143 (5): 549-60. PMC 1575425. PMID 15466450. doi:10.1038/sj.bjp.0705929.
Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C, Dawson M, Van Natta K, Chang LK, Pulido-Rios T, Webber A, Leung E, Eglen RM, Martin GR (Jul 1999). «RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist». British Journal of Pharmacology 127 (5): 1075-82. PMC 1566110. PMID 10455251. doi:10.1038/sj.bjp.0702632.
Dunlop J, Lock T, Jow B, Sitzia F, Grauer S, Jow F, Kramer A, Bowlby MR, Randall A, Kowal D, Gilbert A, Comery TA, Larocque J, Soloveva V, Brown J, Roncarati R (Mar 2009). «Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide)». The Journal of Pharmacology and Experimental Therapeutics 328 (3): 766-76. PMID 19050173. doi:10.1124/jpet.108.146514.
Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (Feb 1999). «Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist». British Journal of Pharmacology 126 (3): 572-4. PMC 1565856. PMID 10188965. doi:10.1038/sj.bjp.0702350.

archives-ouvertes.fr

hal.archives-ouvertes.fr

Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L (Oct 2002). «Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension». Nature Medicine 8 (10): 1129-35. PMID 12244304. doi:10.1038/nm764.
Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L, Launay JM, Maroteaux L (May 2006). «Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice». The Journal of Pharmacology and Experimental Therapeutics 317 (2): 724-31. PMID 16461587. doi:10.1124/jpet.105.098269.

doi.org

dx.doi.org

Schmuck K, Ullmer C, Engels P, Lübbert H (Mar 1994). «Cloning and functional characterization of the human 5-HT2B serotonin receptor». FEBS Letters 342 (1): 85-90. PMID 8143856. doi:10.1016/0014-5793(94)80590-3.
Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM (June 1995). «The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors». British Journal of Pharmacology 115 (4): 622-8. PMC 1908489. PMID 7582481. doi:10.1111/j.1476-5381.1995.tb14977.x.
Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L (Mar 2008). «Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro». The Journal of Neuroscience 28 (11): 2933-40. PMC 6670669. PMID 18337424. doi:10.1523/JNEUROSCI.5723-07.2008.
Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L (Oct 2002). «Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension». Nature Medicine 8 (10): 1129-35. PMID 12244304. doi:10.1038/nm764.
Nebigil CG, Hickel P, Messaddeq N, Vonesch JL, Douchet MP, Monassier L, György K, Matz R, Andriantsitohaina R, Manivet P, Launay JM, Maroteaux L (Jun 2001). «Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function». Circulation 103 (24): 2973-9. PMID 11413089. doi:10.1161/01.cir.103.24.2973.
Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N (Aug 2008). «5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats». Experimental and Toxicologic Pathology 60 (4–5): 253-62. PMID 18511249. doi:10.1016/j.etp.2008.03.005.
Padhariya, Komal; Bhandare, Richie; Canney, Daniel; Velingkar, Vinay (12 de diciembre de 2017). «Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists». Cardiovascular & Hematological Disorders Drug Targets (en inglés) 17 (2): 86-104. PMID 28676029. doi:10.2174/1871529X17666170703115111.
Neugebauer, Volker (2020), «Serotonin—pain modulation», Handbook of the Behavioral Neurobiology of Serotonin, Handbook of Behavioral Neuroscience 31, Elsevier, pp. 309-320, ISBN 9780444641250, doi:10.1016/b978-0-444-64125-0.00017-7, consultado el 4 de julio de 2022 .
Jaffré F, Callebert J, Sarre A, Etienne N, Nebigil CG, Launay JM, Maroteaux L, Monassier L (Aug 2004). «Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts». Circulation 110 (8): 969-74. PMID 15302781. doi:10.1161/01.CIR.0000139856.20505.57.
Monassier L, Laplante MA, Jaffré F, Bousquet P, Maroteaux L, de Champlain J (Aug 2008). «Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice». Hypertension 52 (2): 301-7. PMID 18591460. doi:10.1161/HYPERTENSIONAHA.107.105551.
Jaffré F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, Monassier L, Mettauer B, Blaxall BC, Launay JM, Maroteaux L (Jan 2009). «Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy». Circulation Research 104 (1): 113-23. PMID 19023134. doi:10.1161/CIRCRESAHA.108.180976.
Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L, Launay JM, Maroteaux L (May 2006). «Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice». The Journal of Pharmacology and Experimental Therapeutics 317 (2): 724-31. PMID 16461587. doi:10.1124/jpet.105.098269.
Diaz SL, Maroteaux L (Sep 2011). «Implication of 5-HT(2B) receptors in the serotonin syndrome». Neuropharmacology 61 (3): 495-502. PMID 21277875. doi:10.1016/j.neuropharm.2011.01.025.
Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL (Dec 2000). «Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications». Circulation 102 (23): 2836-41. PMID 11104741. doi:10.1161/01.CIR.102.23.2836.
Roth BL (Jan 2007). «Drugs and valvular heart disease». The New England Journal of Medicine 356 (1): 6-9. PMID 17202450. doi:10.1056/NEJMp068265.
Cavero, Icilio; Guillon, Jean-Michel (1 de marzo de 2014). «Safety Pharmacology assessment of drugs with biased 5-HT2B receptor agonism mediating cardiac valvulopathy». Journal of Pharmacological and Toxicological Methods (en inglés) 69 (2): 150-161. ISSN 1056-8719. PMID 24361689. doi:10.1016/j.vascn.2013.12.004.
PDB 4IB4
Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, McCorvy JD, Jiang Y, Chu M, Siu FY, Liu W, Xu HE, Cherezov V, Roth BL, Stevens RC (May 2013). «Structural features for functional selectivity at serotonin receptors». Science 340 (6132): 615-9. Bibcode:2013Sci...340..615W. PMC 3644390. PMID 23519215. doi:10.1126/science.1232808.
Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ (Sep 1999). «Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells». British Journal of Pharmacology 128 (1): 13-20. PMC 1571597. PMID 10498829. doi:10.1038/sj.bjp.0702751.
Kennett GA, Trail B, Bright F (Dec 1998). «Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated». Neuropharmacology 37 (12): 1603-10. PMID 9886683. doi:10.1016/S0028-3908(98)00115-4.
McCorvy JD, Wacker D, Wang S, Agegnehu B, Liu J, Lansu K, Tribo AR, Olsen RH, Che T, Jin J, Roth BL (August 2018). «Structural determinants of 5-HT2B receptor activation and biased agonism». Nature Structural & Molecular Biology 25 (9): 787-796. PMC 6237183. PMID 30127358. doi:10.1038/s41594-018-0116-7.
Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL (Oct 2009). «Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment». Molecular Pharmacology 76 (4): 710-22. PMC 2769050. PMID 19570945. doi:10.1124/mol.109.058057.
Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (Jun 2003). «3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro». Molecular Pharmacology 63 (6): 1223-1229. PMID 12761331. doi:10.1124/mol.63.6.1223.
Ray TS (2010). «Psychedelics and the human receptorome». En Manzoni, Olivier Jacques, ed. PLOS ONE 5 (2): e9019. Bibcode:2010PLoSO...5.9019R. PMC 2814854. PMID 20126400. doi:10.1371/journal.pone.0009019.
Görnemann T, Hübner H, Gmeiner P, Horowski R, Latté KP, Flieger M, Pertz HH (Mar 2008). «Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors». The Journal of Pharmacology and Experimental Therapeutics 324 (3): 1136-45. PMID 18096760. doi:10.1124/jpet.107.133165.
Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D (Sep 2003). «The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways». The Journal of Pharmacology and Experimental Therapeutics 306 (3): 954-64. PMID 12750432. doi:10.1124/jpet.103.051797.
Garnock-Jones, Karly P. (June 2017). «Cariprazine: A Review in Schizophrenia». CNS Drugs 31 (6): 513-525. ISSN 1179-1934. PMID 28560619. doi:10.1007/s40263-017-0442-z.
Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (2006). «Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis». Clinical Neuropharmacology 29 (2): 80-6. PMID 16614540. doi:10.1097/00002826-200603000-00005.
Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (Apr 1998). «Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors». Psychopharmacology 136 (4): 409-14. PMID 9600588. doi:10.1007/s002130050585.
Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP (Nov 2004). «The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo». British Journal of Pharmacology 143 (5): 549-60. PMC 1575425. PMID 15466450. doi:10.1038/sj.bjp.0705929.
Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C, Dawson M, Van Natta K, Chang LK, Pulido-Rios T, Webber A, Leung E, Eglen RM, Martin GR (Jul 1999). «RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist». British Journal of Pharmacology 127 (5): 1075-82. PMC 1566110. PMID 10455251. doi:10.1038/sj.bjp.0702632.
Kovács A, Gacsályi I, Wellmann J, Schmidt E, Szücs Z, Dubreuil V, Nicolas JP, Boutin J, Bózsing D, Egyed A, Tihanyi K, Spedding M, Szénási G (2003). «Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist». Cardiovascular Drugs and Therapy 17 (5–6): 427-34. PMID 15107597. doi:10.1023/B:CARD.0000015857.96371.43.
Dunlop J, Lock T, Jow B, Sitzia F, Grauer S, Jow F, Kramer A, Bowlby MR, Randall A, Kowal D, Gilbert A, Comery TA, Larocque J, Soloveva V, Brown J, Roncarati R (Mar 2009). «Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide)». The Journal of Pharmacology and Experimental Therapeutics 328 (3): 766-76. PMID 19050173. doi:10.1124/jpet.108.146514.
Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (Feb 1999). «Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist». British Journal of Pharmacology 126 (3): 572-4. PMC 1565856. PMID 10188965. doi:10.1038/sj.bjp.0702350.

eurekaselect.com

Padhariya, Komal; Bhandare, Richie; Canney, Daniel; Velingkar, Vinay (12 de diciembre de 2017). «Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists». Cardiovascular & Hematological Disorders Drug Targets (en inglés) 17 (2): 86-104. PMID 28676029. doi:10.2174/1871529X17666170703115111.

guidetopharmacology.org

«promethazine | Activity data visualisation tool | IUPHAR/BPS Guide to PHARMACOLOGY». www.guidetopharmacology.org. Consultado el 28 de febrero de 2019.

harvard.edu

adsabs.harvard.edu

PDB 4IB4
Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, McCorvy JD, Jiang Y, Chu M, Siu FY, Liu W, Xu HE, Cherezov V, Roth BL, Stevens RC (May 2013). «Structural features for functional selectivity at serotonin receptors». Science 340 (6132): 615-9. Bibcode:2013Sci...340..615W. PMC 3644390. PMID 23519215. doi:10.1126/science.1232808.
Ray TS (2010). «Psychedelics and the human receptorome». En Manzoni, Olivier Jacques, ed. PLOS ONE 5 (2): e9019. Bibcode:2010PLoSO...5.9019R. PMC 2814854. PMID 20126400. doi:10.1371/journal.pone.0009019.

inserm.fr

hal.inserm.fr

Diaz SL, Maroteaux L (Sep 2011). «Implication of 5-HT(2B) receptors in the serotonin syndrome». Neuropharmacology 61 (3): 495-502. PMID 21277875. doi:10.1016/j.neuropharm.2011.01.025.

issn.org

portal.issn.org

Cavero, Icilio; Guillon, Jean-Michel (1 de marzo de 2014). «Safety Pharmacology assessment of drugs with biased 5-HT2B receptor agonism mediating cardiac valvulopathy». Journal of Pharmacological and Toxicological Methods (en inglés) 69 (2): 150-161. ISSN 1056-8719. PMID 24361689. doi:10.1016/j.vascn.2013.12.004.
Garnock-Jones, Karly P. (June 2017). «Cariprazine: A Review in Schizophrenia». CNS Drugs 31 (6): 513-525. ISSN 1179-1934. PMID 28560619. doi:10.1007/s40263-017-0442-z.

nih.gov

ncbi.nlm.nih.gov

«Entrez Gene: HTR_2B 5-hydroxytryptamine (serotonin) receptor 2B».
Schmuck K, Ullmer C, Engels P, Lübbert H (Mar 1994). «Cloning and functional characterization of the human 5-HT2B serotonin receptor». FEBS Letters 342 (1): 85-90. PMID 8143856. doi:10.1016/0014-5793(94)80590-3.
Frazer, Alan; Hensler, Julie G. (1999). «Serotonin». Basic Neurochemistry: Molecular, Cellular and Medical Aspects (en inglés) (6th edición).
Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM (June 1995). «The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors». British Journal of Pharmacology 115 (4): 622-8. PMC 1908489. PMID 7582481. doi:10.1111/j.1476-5381.1995.tb14977.x.
Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L (Mar 2008). «Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro». The Journal of Neuroscience 28 (11): 2933-40. PMC 6670669. PMID 18337424. doi:10.1523/JNEUROSCI.5723-07.2008.
Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L (Oct 2002). «Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension». Nature Medicine 8 (10): 1129-35. PMID 12244304. doi:10.1038/nm764.
Nebigil CG, Hickel P, Messaddeq N, Vonesch JL, Douchet MP, Monassier L, György K, Matz R, Andriantsitohaina R, Manivet P, Launay JM, Maroteaux L (Jun 2001). «Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function». Circulation 103 (24): 2973-9. PMID 11413089. doi:10.1161/01.cir.103.24.2973.
Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N (Aug 2008). «5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats». Experimental and Toxicologic Pathology 60 (4–5): 253-62. PMID 18511249. doi:10.1016/j.etp.2008.03.005.
Padhariya, Komal; Bhandare, Richie; Canney, Daniel; Velingkar, Vinay (12 de diciembre de 2017). «Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists». Cardiovascular & Hematological Disorders Drug Targets (en inglés) 17 (2): 86-104. PMID 28676029. doi:10.2174/1871529X17666170703115111.
Jaffré F, Callebert J, Sarre A, Etienne N, Nebigil CG, Launay JM, Maroteaux L, Monassier L (Aug 2004). «Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts». Circulation 110 (8): 969-74. PMID 15302781. doi:10.1161/01.CIR.0000139856.20505.57.
Monassier L, Laplante MA, Jaffré F, Bousquet P, Maroteaux L, de Champlain J (Aug 2008). «Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice». Hypertension 52 (2): 301-7. PMID 18591460. doi:10.1161/HYPERTENSIONAHA.107.105551.
Jaffré F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, Monassier L, Mettauer B, Blaxall BC, Launay JM, Maroteaux L (Jan 2009). «Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy». Circulation Research 104 (1): 113-23. PMID 19023134. doi:10.1161/CIRCRESAHA.108.180976.
Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L, Launay JM, Maroteaux L (May 2006). «Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice». The Journal of Pharmacology and Experimental Therapeutics 317 (2): 724-31. PMID 16461587. doi:10.1124/jpet.105.098269.
Diaz SL, Maroteaux L (Sep 2011). «Implication of 5-HT(2B) receptors in the serotonin syndrome». Neuropharmacology 61 (3): 495-502. PMID 21277875. doi:10.1016/j.neuropharm.2011.01.025.
Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL (Dec 2000). «Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications». Circulation 102 (23): 2836-41. PMID 11104741. doi:10.1161/01.CIR.102.23.2836.
Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (Jan 2000). «Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine». Molecular Pharmacology 57 (1): 75-81. PMID 10617681.
Roth BL (Jan 2007). «Drugs and valvular heart disease». The New England Journal of Medicine 356 (1): 6-9. PMID 17202450. doi:10.1056/NEJMp068265.
Cavero, Icilio; Guillon, Jean-Michel (1 de marzo de 2014). «Safety Pharmacology assessment of drugs with biased 5-HT2B receptor agonism mediating cardiac valvulopathy». Journal of Pharmacological and Toxicological Methods (en inglés) 69 (2): 150-161. ISSN 1056-8719. PMID 24361689. doi:10.1016/j.vascn.2013.12.004.
PDB 4IB4
Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, McCorvy JD, Jiang Y, Chu M, Siu FY, Liu W, Xu HE, Cherezov V, Roth BL, Stevens RC (May 2013). «Structural features for functional selectivity at serotonin receptors». Science 340 (6132): 615-9. Bibcode:2013Sci...340..615W. PMC 3644390. PMID 23519215. doi:10.1126/science.1232808.
Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, Sheardown MJ (Sep 1999). «Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells». British Journal of Pharmacology 128 (1): 13-20. PMC 1571597. PMID 10498829. doi:10.1038/sj.bjp.0702751.
Kennett GA, Trail B, Bright F (Dec 1998). «Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated». Neuropharmacology 37 (12): 1603-10. PMID 9886683. doi:10.1016/S0028-3908(98)00115-4.
McCorvy JD, Wacker D, Wang S, Agegnehu B, Liu J, Lansu K, Tribo AR, Olsen RH, Che T, Jin J, Roth BL (August 2018). «Structural determinants of 5-HT2B receptor activation and biased agonism». Nature Structural & Molecular Biology 25 (9): 787-796. PMC 6237183. PMID 30127358. doi:10.1038/s41594-018-0116-7.
Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL (Oct 2009). «Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment». Molecular Pharmacology 76 (4): 710-22. PMC 2769050. PMID 19570945. doi:10.1124/mol.109.058057.
Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (Jun 2003). «3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro». Molecular Pharmacology 63 (6): 1223-1229. PMID 12761331. doi:10.1124/mol.63.6.1223.
Ray TS (2010). «Psychedelics and the human receptorome». En Manzoni, Olivier Jacques, ed. PLOS ONE 5 (2): e9019. Bibcode:2010PLoSO...5.9019R. PMC 2814854. PMID 20126400. doi:10.1371/journal.pone.0009019.
Görnemann T, Hübner H, Gmeiner P, Horowski R, Latté KP, Flieger M, Pertz HH (Mar 2008). «Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors». The Journal of Pharmacology and Experimental Therapeutics 324 (3): 1136-45. PMID 18096760. doi:10.1124/jpet.107.133165.
Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D (Sep 2003). «The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways». The Journal of Pharmacology and Experimental Therapeutics 306 (3): 954-64. PMID 12750432. doi:10.1124/jpet.103.051797.
Garnock-Jones, Karly P. (June 2017). «Cariprazine: A Review in Schizophrenia». CNS Drugs 31 (6): 513-525. ISSN 1179-1934. PMID 28560619. doi:10.1007/s40263-017-0442-z.
Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B (2006). «Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis». Clinical Neuropharmacology 29 (2): 80-6. PMID 16614540. doi:10.1097/00002826-200603000-00005.
Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (Apr 1998). «Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors». Psychopharmacology 136 (4): 409-14. PMID 9600588. doi:10.1007/s002130050585.
Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP (Nov 2004). «The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo». British Journal of Pharmacology 143 (5): 549-60. PMC 1575425. PMID 15466450. doi:10.1038/sj.bjp.0705929.
Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C, Dawson M, Van Natta K, Chang LK, Pulido-Rios T, Webber A, Leung E, Eglen RM, Martin GR (Jul 1999). «RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist». British Journal of Pharmacology 127 (5): 1075-82. PMC 1566110. PMID 10455251. doi:10.1038/sj.bjp.0702632.
Kovács A, Gacsályi I, Wellmann J, Schmidt E, Szücs Z, Dubreuil V, Nicolas JP, Boutin J, Bózsing D, Egyed A, Tihanyi K, Spedding M, Szénási G (2003). «Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist». Cardiovascular Drugs and Therapy 17 (5–6): 427-34. PMID 15107597. doi:10.1023/B:CARD.0000015857.96371.43.
Dunlop J, Lock T, Jow B, Sitzia F, Grauer S, Jow F, Kramer A, Bowlby MR, Randall A, Kowal D, Gilbert A, Comery TA, Larocque J, Soloveva V, Brown J, Roncarati R (Mar 2009). «Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide)». The Journal of Pharmacology and Experimental Therapeutics 328 (3): 766-76. PMID 19050173. doi:10.1124/jpet.108.146514.
Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (Feb 1999). «Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist». British Journal of Pharmacology 126 (3): 572-4. PMC 1565856. PMID 10188965. doi:10.1038/sj.bjp.0702350.

nytimes.com

archive.nytimes.com

«Archive: How Fen-Phen, a Diet 'Miracle,' Rose and Fell». archive.nytimes.com. Consultado el 4 de julio de 2022.

opus-bayern.de

Copia archivada (Tesis). Archivado desde el original el 18 de julio de 2011. Consultado el 18 de mayo de 2023.

rcsb.org

PDB 4IB4
Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, McCorvy JD, Jiang Y, Chu M, Siu FY, Liu W, Xu HE, Cherezov V, Roth BL, Stevens RC (May 2013). «Structural features for functional selectivity at serotonin receptors». Science 340 (6132): 615-9. Bibcode:2013Sci...340..615W. PMC 3644390. PMID 23519215. doi:10.1126/science.1232808.

researchgate.net

Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (Jun 2003). «3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro». Molecular Pharmacology 63 (6): 1223-1229. PMID 12761331. doi:10.1124/mol.63.6.1223.

sciencedirect.com

Cavero, Icilio; Guillon, Jean-Michel (1 de marzo de 2014). «Safety Pharmacology assessment of drugs with biased 5-HT2B receptor agonism mediating cardiac valvulopathy». Journal of Pharmacological and Toxicological Methods (en inglés) 69 (2): 150-161. ISSN 1056-8719. PMID 24361689. doi:10.1016/j.vascn.2013.12.004.

unc.edu

pdsp.unc.edu

«PDSP Ki database, University of North Carolina at Chapel Hill». Consultado el 4 de septiembre de 2019.

web.archive.org

Copia archivada (Tesis). Archivado desde el original el 18 de julio de 2011. Consultado el 18 de mayo de 2023.
«Metadoxine extended release (MDX) for adult ADHD». Alcobra Ltd. 2014. Archivado desde el original el 13 de febrero de 2019. Consultado el 7 de mayo de 2014.

worldcat.org

XPharm : the comprehensive pharmacology reference. S. J. Enna, David B. Bylund, Elsevier Science. Amsterdam: Elsevier. 2008. ISBN 978-0-08-055232-3. OCLC 712018683.